Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
Find out how Sensorion’s SENS-601 regulatory push could reshape GJB2 hearing loss gene therapy and clinical strategy.
Pharma & Biotech
Pharma & Biotech
GenSight Biologics begins LHON treatment under France compassionate access as REVISE Phase II moves forward
GenSight Biologics begins treating ND4-LHON patients under France's AAC compassionate access program. Analyse what REVISE and AAC mean for the regulatory pathway.
Pharma & Biotech
What GenSight Biologics’ French CUA decision means for LHON gene therapy
France grants compassionate use access to GenSight Biologics’ LUMEVOQ for LHON. Explore what this decision changes and what risks remain.